FDA, Vyloy and gastric
Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy
After a prior rejection, Astellas can head into the weekend celebrating a class-first FDA approval for its new gastric cancer med Vyloy. | Astellas' Vyloy won an FDA approval to treat gastric or gastroesophageal junction adenocarcinoma patients whose tumors are CLDN18.
The U.S. Food and Drug Administration (FDA) has approved the fourth indication for AbbVie's (NYSE:ABBV) anti-wrinkle therapy ...
The FDA on Thursday approved an injectable drug that eased Parkinson's disease symptoms and improved motor fluctuations in ...
The U.S. Food and Drug Administration has approved Avadel Pharmaceuticals' sleep disorder drug for children aged 7 years and ...
The FDA has just approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa).
Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for motor ...
The FDA has approved the Minima stent system, the first device specifically designed for infants and young children with congenital heart defects. The innovative stent could help thousands of ...
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
The study highlights a breast cancer drug's potential for treating rare appendix cancer, showing promising results in a ...
Brooke, a Northeastern University student, shares what it means to take Opill, the first FDA-approved over-the-counter birth ...
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell ...
Read more on CorMedix (CRMD)'s FDA-approved DefenCath and its potential in the CRBSI market, but be cautious of stock spikes ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback